Profile data is unavailable for this security.
About the company
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
- Revenue in USD (TTM)517.46m
- Net income in USD30.57m
- Incorporated2001
- Employees642.00
- LocationANI Pharmaceuticals Inc210 Main Street WestBAUDETTE 56623United StatesUSA
- Phone+1 (218) 634-3500
- Fax+1 (218) 634-3540
- Websitehttps://www.anipharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 224.60m | 8.49m | 1.24bn | 414.00 | 194.20 | -- | 92.12 | 5.52 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.25bn | 244.00 | -- | 4.53 | -- | 29.30 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.28bn | 171.00 | -- | 2.11 | -- | 62.69 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.29bn | 85.00 | -- | 2.27 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.33bn | 58.00 | -- | 1.57 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.36bn | 642.00 | 40.62 | 3.01 | 14.49 | 2.62 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.37bn | 297.00 | 226.76 | 3.17 | 126.19 | 4.54 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.39bn | 536.00 | -- | -- | -- | 3.91 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.42bn | 711.00 | 23.55 | 1.59 | 9.80 | 2.08 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.42bn | 33.00 | -- | 9.53 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.44bn | 587.00 | -- | 0.9288 | -- | 18.08 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.45bn | 280.00 | -- | 2.36 | -- | 8.93 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.45bn | 58.00 | 15.44 | 1.80 | 10.99 | 12.27 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Arcus Biosciences Inc | 237.00m | -231.00m | 1.46bn | 577.00 | -- | 2.06 | -- | 6.14 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.47bn | 1.60k | -- | 0.4102 | -- | 1.98 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to ANI Pharmaceuticals Inc's reporting currency: US Dollar USD
38.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.31m | 11.01% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.27m | 6.05% |
| Rubric Capital Management LPas of 31 Mar 2024 | 958.53k | 4.57% |
| Deep Track Capital LPas of 31 Mar 2024 | 822.00k | 3.92% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 609.17k | 2.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 574.84k | 2.74% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 490.27k | 2.34% |
| Ranger Investment Management LPas of 31 Mar 2024 | 402.20k | 1.92% |
| Global Alpha Capital Management Ltd.as of 31 Mar 2024 | 390.75k | 1.86% |
| Geode Capital Management LLCas of 31 Mar 2024 | 339.36k | 1.62% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
